Ambulatory pH monitoring: New advances and indications

Gastroenterology and Hepatology

Volumn 2, Issue 11, 2006, Pages 835-842

  Lutsi, Brant ^b   Hirano, Ikuo ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Bilitec; Chest pain; Gastroesophageal reflux disease; Impedance; Laryngitis; Ph monitoring

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; BICARBONATE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACID TOLERANCE; AMBULATORY MONITORING; BILE REFLUX; BILIARY TRACT EXAMINATION; CAPSULE ENDOSCOPE; CAPSULE ENDOSCOPY; CATHETER; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; ESOPHAGEAL PH MONITORING; ESOPHAGUS EXAMINATION; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; GOLD STANDARD; HUMAN; IMPEDANCE; INTERMETHOD COMPARISON; PATIENT CARE; PH MEASUREMENT; REFLUX ESOPHAGITIS; REVIEW; TECHNICAL AID; TELEMETRY; TREATMENT DURATION;

EID: 34548255622     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol. 2003;98:740-749.
2. Pandolfino JE, Schreiner MA, Lee TJ, et al. Comparison of the Bravo wireless and Digitrapper catheter-based pH monitoring systems for measuring esophageal acid exposure. Am J Gastroenterol. 2005;100:1466-1476.
3. Pandolfino JE, Schreiner MA, Ghosh S, et al. Acid reflux event detection using the Bravo wireless versus the Slimline catheter pH systems: why are the numbers so different? Gut. 2005;54:1687-1692.
4. Wong WM, Bautista J, Dekel R et al. Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring - a randomized trial. Aliment Pharmacol Ther. 2005;21:155-163.
5. Pandolfino JE, Bianchi LK, Lee TJ, et al. Esophagogastric junction morphology predicts susceptibility to exercise-induced reflux. Am J Gastroenterol. 2004;99:1430-1436.
6. Aksglaede K, Funch-Jensen P, Thommesen P. Intra-esophageal pH probe movement during eating and talking. A videoradiographic study. Acta Radiol. 2003;44:131-135.
7. Anggiansah A, Sumboonnanonda K, Wang J, et al. Significantly reduced acid detection at 10 centimeters compared to 5 centimeters above lower esophageal sphincter in patients with acid reflux. Am J Gastroenterol. 1993;88:842-846.
8. Fletcher J, Wirz A, Henry E, McColl KE. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut. 2004;53:168-173.
9. Pandolfino J, Schreiner M, Zhang Q, et al. Comparison of esophageal acid exposure at 1 cm and 6 cm above the squamocolumnar junction using the Bravo pH monitoring system. Dis Esophagus. 2006;19:177-182.
10. Ward EM. DeVault KR, Bouras EP, et al. Successful oesophageal pH monitoring with a catheter-free system. Aliment Pharmacol Ther. 2004;19:449-454.
11. Ahlawat SK, Novak DJ, Williams DC, Maher KA et al. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system. J Clin Gastroenterol. 2006;40:20-24.
12. Fajardo NR, Wise JC, Locke GR, et al. Esophageal perforation after placement of wireless Bravo pH probe. Gastrointest Endosc. 2005;63:84-85.
13. Emde C, Garner A, Blum AL. Technical aspects of intraluminal pH-metry in man: current status and recommendations. Gut. 1987;28:1177-1188.
14. Ergun GA, Kahrilas PJ. Clinical applications of esophageal manometry and pH monitoring. Am J Gastroenterol. 1996;91:1077-1089.
15. Wiener GJ, Morgan TM, Copper JB, et al. Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci. 1988;33:1127-1133.
16. Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2005;3:1083-1088.
17. Arora AS, Murray JA. Streamlining 24-hour pH study for GERD: Use of a 3-hour postprandial test. Dig Dis Sci. 2003;48:10-15.
18. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2005;3:329-334.
19. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005;100: 283-289.
20. Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol. 2004;99:991-996.
21. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol. 1996;91:1532-1538.
22. Weusten BL, Roelofs JM, Akkermans LM, et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology. 1994;107:1741-1745.
23. Taghavi SA, Ghasedi M, Saberi-Firoozi M, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut. 2005;54:1067-1071.
24. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl 1):59-67.
25. Katz, PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998;12:1231-1234.
26. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632.
27. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003;98:545-550.
28. Hicks DM, Ours TM, Abelson TI, et al. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice. 2002;16:564-579.
29. Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther. 2003;17:1553-1558.
30. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709-714.
31. Bechi P, Pucciani F, Baldini F, et al. Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic Technique. Dig Dis Sci. 1993;38:1297-1306.
32. Vaezi MF, Singh S, Richter JE. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology. 1995;108:1897-1907.
33. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology. 1994;107:747-754.
34. Marshall RE, Anggiansah A, Manifold DK, et al. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut. 1998;43:603-606.
35. Netzer P, Gut A, Brundler R, et al. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther. 2001;15:1375-1384.
36. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981-988.
37. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52:1397-1402.
38. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53:1024-1031.
39. Shay SS, Bomeli S, Richter J. Multichannel intraluminal impedance accurately detects fasting, recumbent reflux events and their clearing. Am J Physiol Gastrointest Liver Physiol. 2002;283:G376-G383.
40. Zerbib F, Roman S, Pouderooux P, et al. 24 hour ambulatory esophageal multichannel intraluminal impedance-pH in healthy European subjects. Gastroenterology. 2005;128:A-396.
41. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599-1606.
42. Shay S. Esophageal impedance monitoring: the ups and downs of a new test. Am J Gastroenterol. 2004;99:1020-1022.
43. Bredenoord AJ, Weusten BL, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol. 2006;101:453-459.
44. Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg. 1999;117:572-580.
45. Fass R, Hell RW, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut. 2001;48:310-313.
46. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1994;89:989-991.
47. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis. 2000;18:20-26.
48. Robinson M, Maton PN, Allen ML, et al. Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. Aliment Pharmacol Ther. 1991;5:645-651.
49. Robinson M, Maton PN, Rodriguez S, et al. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1997;11:973-980.
50. Katzka DA, Paoletti V, Leite L, Castell DO. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol. 1996;91:2110-2113.
51. Tack J. The Esophagus and non-cardiac chest pain. In: Castell DO, Richter JE, eds. The Esophagus, 4th ed. 2004. Philadedlphia. Lippincott, Williams & Wilkins. p. 634-647.
52. Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol. 2005;100:1226-1232.
53. Pass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology. 1998;115:42-49.
54. Ofman JJ, Gralnek IM, Udani J, et al. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med. 1999;107:219-227.
55. Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology. 1995;109:1575-1582.
56. Ulualp SO, Toohill RJ, Shaker R. Outcomes of acid suppressive therapy in patients with posterior laryngitis. Otolaryngol Head Neck Surg. 2001;124:16-22.
57. Sifrim D, Dupont L, Blondeau K, et al. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut. 2005;54:449-454.
58. Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Intermittent spatial separation of diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. Gastroenterology. 2006;130:334-340.